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INTRODUCTION
Despite a declining incidence in many developed countries,
gastric cancer remains the second most common cause of can-
cer-related deaths in the world (1) and the most common can-
cer in Korea (2, 3). Although the prognosis for advanced gas-
tric cancer is poor, combination chemotherapy has improved
the quality of life and overall survival compared with the best
supportive care in several randomized studies (4-6). 
In general, 5-fluorouracil (5-FU)-based or cisplatin-based
combination regimens are widely accepted as potential stan-
dard therapies with a response rate of around 25-40% and
median overall survival of 7-9 months (7). Although a larger
proportion of patients with metastatic or recurrent gastric can-
cer initially respond to chemotherapy, they ultimately prog-
ress. In addition, a significant proportion of patients have pri-
mary refractory diseases. For these patients, there is no cur-
rently established second-line treatment option. 
Irinotecan is a hemi-synthetic, water-soluble derivative of
the plant alkaloid camptothecin. After conversion to its active
metabolite, SN-38, irinotecan acts by inhibiting the eukary-
otic enzyme DNA-topoisomerase I (8, 9). As such, irinotecan
has shown promising activity in advanced gastric cancer as a
single agent or combined with different doses and schedules
of cisplatin (10-13). Boku et al. (12) reported a high response
rate using a combination of irinotecan and cisplatin against
advanced gastric cancer, with an overall response rate of 59%
in chemotherapy-naive patients. Ajani et al. (13) also reported
a good response rate for irinotecan and cisplatin against ad-
vanced gastric or gastro-esophageal junction carcinoma, with
an overall response rate of 51%. However, there is very little
data evaluating the efficacy of irinotecan in pretreated patients
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Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in
Pretreated Patients with Advanced Gastric Cancer: A Multicenter
Phase II Study
The current phase II study was conducted to evaluate the response rate and safety
of a combination regimen of biweekly irinotecan plus cisplatin in pretreated patients
with advanced gastric cancer. Patients with previously treated metastatic or recur-
rent gastric cancer received intravenous irinotecan 70 mg/m
2 and cisplatin 30
mg/m
2 on day 1 and 15 every 4-week cycle. Thirty-two patients were enrolled in the
current study. Of these, 31 patients were assessable for efficacy and all for toxicity.
No complete response and 5 partial responses were confirmed, giving an overall
response rate of 15.6% (95% CI; 2.3-28.9%). The median time to progression and
median overall survival for all patients was 113 days and 184 days, respectively.
Grade 3/4 neutropenia occurred in 6 patients (18.8%), yet no febrile neutropenia
was observed. In addition, grade 3 anorexia was observed in 4 patients (12.5%)
and grade 3 diarrhea occurred in 2 patients (6.2%). The combination chemotherapy
of biweekly irinotecan and cisplatin was found to be moderately effective and well
tolerated in pretreated patients with advanced gastric cancer. Accordingly, this regi-
men can be regarded as an important second-line treatment option for advanced
gastric cancer.
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with advanced gastric cancer.
Accordingly, the current phase II trial evaluated the response
rate, safety, and time to progression of biweekly irinotecan
and cisplatin as a second-line chemotherapy in pretreated pa-
tients with advanced gastric cancer.
MATERIALS AND METHODS
Eligibility
The current multi-center phase II study included patients
who had histologically confirmed metastatic or recurrent gas-
tric adenocarcinoma with at least one unidimensionally mea-
surable lesion, and who had previously received at least one
palliative chemotherapy regimen that did not include a topoi-
somerase I inhibitor. The patients were 18-75 yr of age with
a performance status of 0-2 on the Eastern Cooperative Oncol-
ogy Group (ECOG) scale. In addition, adequate hematological
(WBC count ≥4×10
9/L, platelet count ≥100×10
9/L,
hemoglobin ≥9 g/dL), renal (serum creatinine ≤1.5 mg/dL
and creatinine clearance ≥50 mL/min), and hepatic (total
bilirubin ≤2.0 mg/dL and serum transaminase level ≤3
times the upper limit of the normal range) levels were also
required. Patients were ineligible if they had other severe
medical illnesses, CNS metastasis, another active malignan-
cy, or history of anaphylaxis to drugs. Written informed con-
sent was obtained from all patients before enrollment.
Study treatment
The irinotecan and cisplatin were administered on days 1
and 15 every 4 weeks. The irinotecan (70 mg/m
2) was dis-
solved in 500 mL 5% glucose and was infused intravenous-
ly over 90 min, and the cisplatin (30 mg/m
2) was dissolved
in 150 mL saline and was infused intravenously over 60 min.
To maintain hydration, a total of 2,000-3,000 mL intravenous
fluid was administered. All patients were premedicated with
steroids and 5-HT3 inhibitors to prevent emesis. Treatment
was continued until disease progression, patient refusal, or an
unacceptable toxicity up to 6 cycles.
Dose modification
Treatment was continued at the same dose if patients expe-
rienced grade 1 toxicities or other toxicities considered by the
investigator unlikely to become serious or life threatening (e.g.,
alopecia). For all other treatment-related adverse events with
a grade 2 intensity or higher, the dose modification scheme
described below was implemented. No dose reduction was
applied after the first appearance of a grade 2 toxicity, although
treatment was interrupted until the toxicity was resolved to
grade 0 to 1 and symptomatic treatment initiated where pos-
sible. The dose of irinotecan was reduced by 25% in patients
who experienced a second occurrence of a given grade 2 tox-
icity or any grade 3 toxicity. The irinotecan and cisplatin ther-
apy was discontinued if the toxicities did not resolve to grade
0 or 1 within 2 weeks. If patients experienced a third occur-
rence of a given grade 2 toxicity, a second occurrence of a given
grade 3 toxicity, or any grade 4 toxicity, the irinotecan dose
was reduced by 50%. The irinotecan and cisplatin were both
discontinued if, despite a dose reduction, a given toxicity oc-
curred for a fourth time at grade 2, a third time at grade 3,
or a second time at grade 4. Patients were required to meet
all the following criteria to begin the next cycle of treatment:
platelet count ≥75×10
9/L; neutrophil count ≥1.5×10
9/L;
resolution or improvement of clinically significant non-hema-
tological adverse events (including diarrhea and mucositis) to
grade 0 or 1. If treatment was delayed for 3 weeks, patients
were excluded from the study.
Study assessments
A screening assessment, including a medical history, physi-
cal examination, ECG, chest radiography, and tumor assess-
ment, was conducted within 2 weeks before starting treat-
ment. Further assessments were also conducted within 7 days
before starting treatment, including vital signs, an ECOG per-
formance status, and laboratory tests (hematology, blood che-
mistry, and urinalysis). Complete blood counts were performed
weekly during the first cycle and biweekly during every cycle
thereafter, and biochemical tests performed before each cycle.
Tumors were measured every two cycles until the tumor pro-
gressed. The tumor responses were classified according to the
response evaluation criteria in solid tumors (RECIST) guide-
lines (14); complete response (CR), the disappearance of all
target lesions; partial response (PR), a decrease of at least 30%
in the sum of the longest diameters of the target lesions; pro-
gressive disease (PD), an increase of at least 20% in the sum
of the longest diameters of the target lesions or the appearance
of one or more new lesions; stable disease (SD), neither suffi-
cient shrinkage to qualify for PR nor sufficient increase to
qualify for PD. Patients with a CR or PR required a confir-
matory disease assessment at least 4 weeks later. Adverse events
were graded according to National Cancer Institute Common
Toxicity Criteria (NCI-CTC) version 2.0.
Statistical analysis
This trial was designed to detect a response rate of 20% as
compared to a minimal, clinically meaningful response rate
of 5%. A two-stage optimal design proposed by Simon was
used for this trial, with 80% power to accept the hypothesis
and 5% significance to reject the hypothesis. Allowing for a
follow-up loss rate of up to 10%, the total sample size was to
be 32 patients with measurable disease. All enrolled patients
were included in the intention-to-treat analysis of efficacy. The
time to progression and survival analyses were all estimated968 J.H. Baek, J.G. Kim, S.K. Sohn, et al.
using the Kaplan-Meier method. The time to progression was
calculated from the initiation of second-line chemotherapy to
the date of disease progression, and overall survival was mea-
sured from the initiation of second-line chemotherapy to the
date of the last follow-up or death. The statistical data were
obtained using an SPSS software package (SPSS 11.5 Inc. Chi-
cago, IL, U.S.A.).
RESULTS
Patient characteristics
A total of 32 patients were enrolled from 5 medical centers
in Korea. The characteristics of the patients are summarized
in Table 1. The median age was 54 (range, 27-69) yr, and
there were 27 males and 5 females. Many patients (71.9%)
had a good performance status (ECOG 0 or 1). Twenty-four
(75.0%) patients had a metastatic disease, while 8 patients
had a recurrent disease after surgical resection (total or subto-
tal gastrectomy) of the primary tumor. Distal lymph nodes
and the liver were the most common sites of the metastases
or recurrences. 
Prior treatments
The prior treatments are summarized in Table 2. Sixteen
patients had previously undergone surgery, one patient had
received palliative radiation, and four patients had received 5-
FU-based adjuvant chemotherapy. The prior palliative chemo-
therapies were paclitaxel-based chemotheraoy (62.5%) or doc-
etaxel-based chemotherapy (37.5%), where cisplatin was com-
bined in 10 (31.3%) patients. The responses included 1 CR
(3.1%), 10 PR (31.3%), 7 SD (21.9%), and 14 PD (43.8%).
Efficacy
Thirty-one (96.9%) of the 32 patients were assessable for
response due to one loss of follow-up. All efficacy data are re-
ported using the intention-to-treat patient population. No
CR and 5 PR were confirmed, giving an overall response rate
of 15.6% (95% CI; 2.3-28.9%). The response characteristics
are shown in Table 3. The median time to progression for all
patients was 113 (95% CI; 97-129) days (Fig. 1) with a medi-
an follow-up duration of 177 days. Ten patients (31.3%) re-
ceived third-line chemotherapy after irinotecan and cisplatin
failure, and most (90.0%) of these third-line chemotherapy
regimens were capecitabine monotherapy. Twenty-two patients
had died at the time of the present evaluation. The median
overall survival was 184 (95% CI; 153-215) days with an es-
timated 1-yr survival rate of 21.0% (Fig. 2).
Toxicity
The hematological and non-hematological toxicities are
summarized in Table 4. A total of 116 cycles (median 3, range
1-6 cycles) were administrated to 32 patients assessable for
toxicity. The most severe hematological adverse event was
neutropenia, which occurred with a grade 3/4 intensity in 6
Characteristic Number of patients (%)
Registered patients 32
Assessable for response 31 (96.9)
Lost to follow-up 1 (3.1)
Age (yr)
Median 54
Range 27-69
Gender
Male 27 (84.4)
Female 5 (15.6)
ECOG performance status
0 1 (3.1)
1 22 (68.8)
2 9 (28.1)
Disease status
Metastatic 24 (75.0)
Recurrent 8 (25.0)
Metatatic or recurrent sites
Distal lymph nodes 23
Liver 14
Peritoneum 7
Ovary 2
Bone 2
Others (lung, kidney, pancreas) 3
Table 1. Patient characteristics
Treatment Number of patients (%)
Surgery
Curative 8 (25.0)
Palliative 8 (25.0)
No 16 (50.0)
Radiotherapy
Adjuvant 0 (0.0)
Palliative 1 (3.1)
No 31 (96.9)
Adjuvant chemotherapy
Yes 4
No 28
Palliative chemotherapeutic regimen
Paclitaxel-based regimen 20 (62.5)
Docetaxel-based regimen 12 (37.5)
Number of cycles 
Median 3.5
Range 1-9
Maximal response to 1st-line regimen
Complete remission 1 (3.1)
Partial remission 10 (31.3)
Stable disease 7 (21.9)
Progressive disease 14 (43.8)
TTP of 1st line regimen (months)
Median 5
Range 2-18
Table 2. Prior treatments
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patients (18.8%) and in 7 cycles (6.0%). Yet, no febrile neu-
tropenia was observed. Anorexia was the most common non-
hematological toxicity. Grade 3/4 anorexia was observed in 4
patients (12.5%) and in 6 cycles (5.2%). Yet, no grade 4 non-
hematologic toxicity was observed. There were no treatment-
related deaths during this study. The dose was reduced in 37
cycles and treatment delayed in 11 cycles. The treatment doses
were modified for the following reasons: hematological toxi-
city (43.2%), anorexia (21.6%), nausea (18.9%), and diarrhea
(16.2%).
DISCUSSION
Although systemic chemotherapy is effective in newly diag-
nosed advanced gastric cancer, second-line chemotherapy for
patients where first-line chemotherapy has failed remains a
challenge. As such, the current study assessed the clinical effi-
cacy and toxicity of a combination chemotherapy of biweek-
ly irinotecan and cisplatin, which could be administered on
an outpatient basis to pretreated patients with advanced gas-
tric cancer. As a result, 5 of 32 (15.6%) enrolled patients achie-
ved an objective response and 15 (46.9%) showed a stable
disease, plus the median time to progression and median over-
all survival was 113 days and 184 days, respectively. Although
the response rate was slightly low, the survival time was com-
parable with previous studies using irinotecan or other agents,
including oxaliplatin, paclitaxel, or docetaxel, as second-line
treatment in patients with pretreated advanced gastric cancer
(15-20).
The major toxicities related to irinotecan are diarrhea and
myelosuppression, which are known to be dose dependent.
Chemotherapy-induced severe diarrhea or neutropenia can also
result in treatment-related hospitalization or mortality, there-
by compromising the quality of life and increasing medical
expenditure. Thus, in consideration of the second-line treat-
ment setting, we chose a tolerable dose and schedule of the
inrinotecan plus cisplatin combination among available reg-
imens showing efficacy against advanced gastric cancer. Ajani
et al. reported that the administration of irinotecan (50 mg/m
2)
and cisplatin (30 mg/m
2) weekly for 4 consecutive weeks with
2 weeks rest showed a response rate of 31%, a time to progres-
sion of 7 weeks, and median overall survival of 5 months in
pretreated patients with advanced adenocarcinoma of the stom-
ach or gastroesophageal junction (15). However, due to the
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Fig. 1. Time to progression for all patients.
N=32
Median=113 (95% Cl; 97-129) days
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Fig. 2. Overall survival for all patients.
N=32
Median=184 (95% Cl; 153-215) days
Response  Number (n=32, %)
Confirmed response 5 (15.6)
Complete response 0 (0)
Partial response 5 (15.6)
Stable disease 15 (46.9)
Progressive disease 11 (34.3)
Not assessable 1 (3.1)
Table 3. Tumor response (intention-to-treat analysis)
Grade Grade 
(% of patients, n=32) (% of cycles, n=116)
Hematologic
Anemia 9.4 - 9.4 2.6 - 2.6
Neutropenia 15.6 3.1 18.8 5.2 0.9 6.0
Thrombocytopenia 6.3 3.1 9.4 3.4 0.9 4.3
Non-hematologic
Fatigue/asthenia 3.1 - 3.1 0.9 - 0.9
Nausea 9.4 - 9.4 3.4 - 3.4
Vomiting 6.3 - 6.3 1.7 - 1.7
Anorexia 12.5 - 12.5 5.2 - 5.2
Diarrhea 6.3 - 6.3 1.7 - 1.7
Constipation 3.1 - 3.1 0.9 - 0.9
Mucositis/stomatitis 9.4 - 9.4 3.4 - 3.4
Abdominal pain 3.1 - 3.1 0.9 - 0.9
Febrile neutropenia - - - - - -
Table 4. Adverse reactions
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high incidence of toxicities, they also suggested that dose and
schedule modifications were warranted to increase the toler-
ability of the regimen. Recently, Chun et al. reported the phase
II study of weekly irinotecan (125 mg/m
2for 4 weeks followed
by 2-week rest) in patients with metastatic gastric cancer fail-
ing cisplatin-based chemotherapy (18). In their study, the ob-
jective response rate was 20% and median overall survival
was 5.2 months, yet 67.6% of patients experienced grade 3/4
neutropenia and 18.9% experienced grade 3 diarrhea. How-
ever, in the current study, only 18.8% and 6.3% of patients
experienced grade 3/4 neutropenia and diarrhea, respectively.
Furthermore, there was no febrile neutropenia, treatment-
related hospitalization, or grade 4 non-hematologic adverse
reaction.
In conclusion, the combination of biweekly irinotecan and
cisplatin was found to be moderately effective and well toler-
ated in pretreated patients with advanced gastric cancer. Accor-
dingly, this regimen can be regarded as an important second-
line treatment option for advanced gastric cancer.
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